KR20250148711A - 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체 - Google Patents

시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체

Info

Publication number
KR20250148711A
KR20250148711A KR1020257029356A KR20257029356A KR20250148711A KR 20250148711 A KR20250148711 A KR 20250148711A KR 1020257029356 A KR1020257029356 A KR 1020257029356A KR 20257029356 A KR20257029356 A KR 20257029356A KR 20250148711 A KR20250148711 A KR 20250148711A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
acid sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257029356A
Other languages
English (en)
Korean (ko)
Inventor
요제프 마리아 헨드릭 래츠
레나토 제라두스 실바노 치리비
요하네스 윌헬무스 제라두스 반 로스말렌
Original Assignee
씨트릴 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1813597.0A external-priority patent/GB201813597D0/en
Priority claimed from GBGB1900983.6A external-priority patent/GB201900983D0/en
Application filed by 씨트릴 비.브이. filed Critical 씨트릴 비.브이.
Publication of KR20250148711A publication Critical patent/KR20250148711A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020257029356A 2018-08-21 2019-08-20 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체 Pending KR20250148711A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1813597.0 2018-08-21
GBGB1813597.0A GB201813597D0 (en) 2018-08-21 2018-08-21 Antibody
GB1900983.6 2019-01-24
GBGB1900983.6A GB201900983D0 (en) 2019-01-24 2019-01-24 Antibody
PCT/EP2019/072302 WO2020038963A1 (en) 2018-08-21 2019-08-20 Antibodies binding to citrullinated histone 2a and/or 4
KR1020217008362A KR102871821B1 (ko) 2018-08-21 2019-08-20 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008362A Division KR102871821B1 (ko) 2018-08-21 2019-08-20 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체

Publications (1)

Publication Number Publication Date
KR20250148711A true KR20250148711A (ko) 2025-10-14

Family

ID=67688785

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257029356A Pending KR20250148711A (ko) 2018-08-21 2019-08-20 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체
KR1020217008362A Active KR102871821B1 (ko) 2018-08-21 2019-08-20 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217008362A Active KR102871821B1 (ko) 2018-08-21 2019-08-20 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체

Country Status (21)

Country Link
US (3) US20210395350A1 (https=)
EP (2) EP3841120B1 (https=)
JP (2) JP7434328B2 (https=)
KR (2) KR20250148711A (https=)
CN (2) CN120058926A (https=)
AU (3) AU2019326740B2 (https=)
CA (1) CA3110013A1 (https=)
DK (1) DK3841120T3 (https=)
ES (1) ES3048210T3 (https=)
FI (1) FI3841120T3 (https=)
HR (1) HRP20251346T1 (https=)
IL (2) IL280995B2 (https=)
LT (1) LT3841120T (https=)
MX (3) MX2025007881A (https=)
PT (1) PT3841120T (https=)
RS (1) RS67385B1 (https=)
SG (1) SG11202101652PA (https=)
SI (1) SI3841120T1 (https=)
SM (1) SMT202500388T1 (https=)
WO (1) WO2020038963A1 (https=)
ZA (1) ZA202101051B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
WO2021209465A1 (en) * 2020-04-14 2021-10-21 Universiteit Maastricht Peptide for the treatment of net-associated diseases
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
GB202012326D0 (en) 2020-08-07 2020-09-23 Citryll B V Diagnostic
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) * 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
NO2294086T3 (https=) 2008-06-04 2018-02-10
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
GB201410520D0 (en) * 2014-06-12 2014-07-30 Univ London Queen Mary Antibody
JP7037940B2 (ja) * 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
US20170038381A1 (en) 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
EP3841120B1 (en) 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
CN117396221A (zh) * 2021-05-04 2024-01-12 奇特里尔私人有限公司 嗜酸性粒细胞陷阱的抑制
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제

Also Published As

Publication number Publication date
IL322482A (en) 2025-09-01
CN112930356A (zh) 2021-06-08
IL280995B1 (en) 2025-09-01
US12590143B2 (en) 2026-03-31
JP2024059670A (ja) 2024-05-01
HRP20251346T1 (hr) 2025-12-19
EP4659807A3 (en) 2026-03-18
JP2021535211A (ja) 2021-12-16
IL280995A (en) 2021-04-29
AU2019326740B2 (en) 2025-11-27
LT3841120T (lt) 2025-11-10
ES3048210T3 (en) 2025-12-09
US20210395350A1 (en) 2021-12-23
RS67385B1 (sr) 2025-11-28
WO2020038963A1 (en) 2020-02-27
AU2026201302A1 (en) 2026-03-12
EP4659807A2 (en) 2025-12-10
MX2025007881A (es) 2025-08-01
ZA202101051B (en) 2022-08-31
KR102871821B1 (ko) 2025-10-16
SI3841120T1 (sl) 2025-12-31
CN112930356B (zh) 2025-03-21
FI3841120T3 (fi) 2025-11-03
AU2019326740A1 (en) 2021-03-18
KR20210056355A (ko) 2021-05-18
EP3841120A1 (en) 2021-06-30
DK3841120T3 (da) 2025-10-20
US20230183327A1 (en) 2023-06-15
MX2021001902A (es) 2021-05-27
CA3110013A1 (en) 2020-02-27
IL280995B2 (en) 2026-01-01
CN120058926A (zh) 2025-05-30
US20210403543A1 (en) 2021-12-30
AU2026201303A1 (en) 2026-03-12
SG11202101652PA (en) 2021-03-30
PT3841120T (pt) 2025-10-20
JP7434328B2 (ja) 2024-02-20
EP3841120B1 (en) 2025-09-24
MX2025007882A (es) 2025-08-01
JP7835788B2 (ja) 2026-03-25
US11345750B2 (en) 2022-05-31
SMT202500388T1 (it) 2025-11-10

Similar Documents

Publication Publication Date Title
KR102871821B1 (ko) 시트룰린화된 히스톤 2a 및/또는 4에 결합하는 항체
US11919947B2 (en) Antibody binding active α-synuclein
KR101947758B1 (ko) 포스포릴콜린에 대한 신규 항체
US20250084154A1 (en) Inhibition of eosinophilic traps
CN105518024A (zh) 人抗il-32抗体
WO2021087462A1 (en) Rage antibodies, fragments and uses thereof
JP2022502369A (ja) α−シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
HK40128527A (en) Antibodies binding to citrullinated histone 2a and/or 4
JP7673981B2 (ja) 抗ｃｘｃｒ２抗体およびその使用
EP4085973A1 (en) Inhibition of eosinophil extracellular traps
EA053252B1 (ru) Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4
EA048367B1 (ru) Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4
CA3071634C (en) Antibody binding active alpha-synuclein
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)